Skip to content

Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes

Evaluation of Biomarkers and Clinical Parameters of Acute Organ Injury in Children With Newly Diagnosed Type 1 Diabetes: The Effect of Diabetic Ketoacidosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07483879
Enrollment
45
Registered
2026-03-19
Start date
2025-06-13
Completion date
2030-03-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Ketoacidosis, Type 1 Diabetes Mellitus

Keywords

Biomarkers, Acute Kidney Injury, Cardiac Biomarkers, NGAL, NT-proBNP, hs-Troponin, Pediatric Type 1 Diabetes, Myocardial Strain Imaging, KIM-1

Brief summary

Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart. Early detection of organ dysfunction is important for identifying children at increased risk for complications. This observational cross-sectional study aims to evaluate biomarkers of acute organ injury and associated clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls. Biomarkers including KIM-1, NGAL, high-sensitivity troponin, NT-proBNP, interleukin-6, and C-reactive protein will be measured during hospital admission and within the first 24-48 hours of hospitalization.

Detailed description

Diabetic ketoacidosis (DKA) is a common and potentially life-threatening metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM). In addition to the acute metabolic disturbances, DKA may lead to early or subclinical injury of vital organs, particularly the kidneys and the cardiovascular system, due to dehydration, hypovolemia, metabolic acidosis, electrolyte disturbances, and inflammatory activation. Recent studies suggest that novel biomarkers may allow early detection of organ dysfunction before conventional clinical indicators become abnormal. Biomarkers such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, high-sensitivity troponin (hs-troponin), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been proposed as sensitive indicators of kidney and myocardial injury. Inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) may also reflect systemic inflammatory activation associated with metabolic decompensation. The aim of this observational cross-sectional study is to investigate and compare biomarkers of acute organ injury and related clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls. Participants will be categorized into three groups: (1) children with newly diagnosed T1DM presenting with DKA, (2) children with newly diagnosed T1DM without DKA, and (3) healthy children serving as controls. Blood samples will be collected at hospital admission for measurement of biomarkers including KIM-1, NGAL, hs-troponin, NT-proBNP, IL-6, and CRP, as well as standard laboratory parameters such as serum creatinine, cystatin C, albuminuria, pH, bicarbonate levels, and HbA1c. All participants with T1DM will undergo cardiological evaluation including clinical examination, electrocardiogram, and transthoracic echocardiography with conventional measurements as well as advanced techniques such as tissue Doppler imaging and speckle-tracking echocardiography. Data collection will be performed at admission and within the first 24-48 hours of hospitalization. The primary objective of the study is to compare biomarker levels and clinical parameters among the three study groups in order to identify early evidence of acute or subclinical organ dysfunction associated with diabetic ketoacidosis in children with newly diagnosed T1DM.

Interventions

DIAGNOSTIC_TESTBiomarker and Echocardiographic Assessment

Blood and urine samples and echocardiographic evaluation performed as part of the clinical assessment of children with newly diagnosed type 1 diabetes.

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to 16 Years
Healthy volunteers
Yes

Inclusion criteria

* Children aged 2-16 years * Newly diagnosed type 1 diabetes mellitus * Hospital admission for initial evaluation and treatment * Presence or absence of diabetic ketoacidosis at diagnosis * Written informed consent from parents or legal guardians For control group: \- Age-matched healthy children without diabetes

Exclusion criteria

* Previous diagnosis of diabetes mellitus * Known chronic kidney disease * Known cardiovascular disease * Acute infection or inflammatory condition unrelated to diabetes * Use of medications that may affect renal or cardiac biomarkers

Design outcomes

Primary

MeasureTime frameDescription
Neutrophil Gelatinase-Associated LipocalinWithin 48 hours of hospitalizationMeasurement of neutrophil gelatinase-associated lipocalin (NGAL, ng/mL) as a biomarker of early renal injury in children with newly diagnosed type 1 diabetes.
Kidney Injury Molecule-1Within 48 hours of hospitalizationMeasurement of kidney injury molecule-1 (KIM-1, ng/mL) as a biomarker of renal injury in children with newly diagnosed type 1 diabetes.
High-Sensitivity TroponinWithin 48 hours of hospitalizationMeasurement of high-sensitivity troponin (hs-troponin, ng/L) as a biomarker of myocardial injury in children with newly diagnosed type 1 diabetes.
N-terminal pro-B-type Natriuretic PeptideWithin 48 hours of hospitalizationMeasurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) as a biomarker of cardiac stress in children with newly diagnosed type 1 diabetes.
Interleukin-6Within 48 hours of hospitalizationMeasurement of interleukin-6 (IL-6, pg/mL) as a biomarker of systemic inflammation in children with newly diagnosed type 1 diabetes.
C-reactive ProteinWithin 48 hours of hospitalizationMeasurement of C-reactive protein (CRP, mg/L) as a biomarker of systemic inflammation in children with newly diagnosed type 1 diabetes.

Secondary

MeasureTime frameDescription
Serum CreatinineWithin 48 hours of hospitalizationMeasurement of serum creatinine (mg/dL) in children with newly diagnosed type 1 diabetes.
Cystatin CWithin 48 hours of hospitalizationMeasurement of and cystatin C (mg/L) in children with newly diagnosed type 1 diabetes.
Left Ventricular Ejection FractionWithin 48 hours of hospitalizationAssessment of left ventricular systolic function using left ventricular ejection fraction measured by transthoracic echocardiography.
Left Ventricular Fractional ShorteningWithin 48 hours of hospitalizationEvaluation of left ventricular systolic function using fractional shortening measured by transthoracic echocardiography.
E/e' RatioWithin 48 hours of hospitalizationAssessment of left ventricular diastolic function using the ratio of transmitral early filling velocity (E) to tissue Doppler early diastolic velocity (e').
Left Ventricular Global Longitudinal StrainWithin 48 hours of hospitalizationAssessment of subclinical left ventricular systolic function using global longitudinal strain derived from speckle-tracking echocardiography.
Glutamic Acid Decarboxylase Antibodies (GAD65)Within 48 hours of hospitalizationMeasurement of glutamic acid decarboxylase antibodies (GAD65) in children with newly diagnosed type 1 diabetes.
Insulin Autoantibodies (IAA)Within 48 hours of hospitalizationMeasurement of insulin autoantibodies (IAA) in children with newly diagnosed type 1 diabetes.
Islet Antigen-2 Antibodies (IA-2)Within 48 hours of hospitalizationMeasurement of islet antigen-2 antibodies (IA-2) in children with newly diagnosed type 1 diabetes.
Zinc Transporter 8 Antibodies (ZnT8)Within 48 hours of hospitalizationMeasurement of zinc transporter 8 antibodies (ZnT8) in children with newly diagnosed type 1 diabetes.
Severity of Diabetic KetoacidosisBaselineClassification of diabetic ketoacidosis severity at hospital admission based on venous blood pH and serum bicarbonate levels according to international pediatric guidelines. Diabetic ketoacidosis will be categorized as mild (pH \<7.30, bicarbonate \<15 mmol/L), moderate (pH \<7.20, bicarbonate \<10 mmol/L), or severe (pH \<7.10, bicarbonate \<5 mmol/L).

Countries

Greece

Contacts

CONTACTAthina Stamati
atstamati@gmail.com+30 6958796612
PRINCIPAL_INVESTIGATORAthanasios Christoforidis

Aristotle University Of Thessaloniki

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026